Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
08:00am, Thursday, 08'th Feb 2024
WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies,
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 28'th Dec 2023
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies,
Why Is Replimune (REPL) Stock Down 48% Today?
11:39am, Tuesday, 05'th Dec 2023
Replimune (NASDAQ: REPL ) stock is falling hard on Tuesday after the clinical-stage biotechnology company shared a primary analysis of its CERPASS trial. This trial is evaluating RP1 alongside cemipl
Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
08:28am, Tuesday, 05'th Dec 2023
Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not
RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated disease RP2 as monotherapy an
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
08:00am, Tuesday, 07'th Nov 2023
The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including:
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
07:30pm, Friday, 03'rd Nov 2023
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients RP1 as monotherapy showed clear anti-tumor activity with an overall respons
Tessellate BIO Emerges from Stealth
03:00am, Tuesday, 17'th Oct 2023
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations Lead program targets Alternative Lengthening o
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 19'th Sep 2023
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherap
Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch
05:28pm, Monday, 14'th Aug 2023
Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of 2023. T
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
08:00am, Thursday, 03'rd Aug 2023
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics Licens
Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment
01:22am, Sunday, 09'th Jul 2023
The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from the CERPASS clinical trial for RP1 combined with L
Replimune to Present at the Jefferies Global Healthcare Conference
04:01pm, Thursday, 01'st Jun 2023
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolyti
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
05:00pm, Thursday, 25'th May 2023
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic imm
